Printed on 3/17/2026
For informational purposes only. This is not medical advice.
The IIEF-5, also known as the Sexual Health Inventory for Men (SHIM), is a 5-item abridged version of the 15-item IIEF questionnaire. It classifies erectile dysfunction as severe (5–7), moderate (8–11), mild-to-moderate (12–16), mild (17–21), or no ED (22–25). It is the most widely used ED screening tool. Cardiovascular disease is the leading organic cause of ED — assess 10-year risk with [ASCVD Risk Calculator](/tools/ascvd-risk) and [Framingham Risk Score](/tools/framingham-risk). Screen for depression, a common cause and consequence of ED, with [PHQ-9](/tools/phq-9). Assess voiding symptoms with [IPSS Calculator](/tools/ipss). Metabolic syndrome increases ED risk — calculate [BMI Calculator](/tools/bmi-calculator).
Formula: Sum of 5 items (each 1–5). Total: 5–25. No ED ≥22, Mild 17–21, Mild-Mod 12–16, Moderate 8–11, Severe 5–7.
Your IIEF-5 score classifies erectile function on a spectrum from normal to severely impaired. A score of 22 to 25 indicates no erectile dysfunction. A score of 17 to 21 indicates mild ED, where erections are generally sufficient but occasionally unreliable. A score of 12 to 16 indicates mild-to-moderate ED, with more frequent difficulty achieving or maintaining erections adequate for satisfactory intercourse. A score of 8 to 11 indicates moderate ED, where erectile difficulties are present in most attempts. A score of 5 to 7 indicates severe ED, with erections rarely adequate for penetration.
The validated diagnostic cutoff for erectile dysfunction is a score of 21 or below. However, clinical significance depends on individual context — a patient's baseline expectations, relationship factors, and the degree to which erectile difficulty causes distress all inform treatment decisions. Serial IIEF-5 scores are useful for monitoring response to PDE5 inhibitors, penile rehabilitation programs, or recovery after pelvic surgery.
The IIEF-5 is the standard screening tool for erectile dysfunction in clinical practice. It should be used at the initial evaluation of any man presenting with ED complaints, during pre-operative assessment before radical prostatectomy or other pelvic surgery (to establish a baseline), and at follow-up visits to objectively measure treatment response to PDE5 inhibitors (sildenafil, tadalafil), intracavernosal injections, or vacuum devices.
It is also widely used in clinical trials as a primary or secondary outcome measure for ED treatments. In primary care, it provides an efficient, standardized way to quantify ED severity and facilitate conversations about sexual health that patients may otherwise find difficult to initiate.
The IIEF-5 focuses specifically on erectile function and does not assess other domains of sexual health such as libido, orgasmic function, ejaculatory function, or overall sexual satisfaction. Men with premature ejaculation, low desire, or anorgasmia may score normally on the IIEF-5 despite significant sexual dysfunction. The full 15-item IIEF covers these additional domains.
The questionnaire requires recent sexual activity or attempts for meaningful responses. Men who have not been sexually active may have difficulty answering, and their scores may not accurately reflect erectile capacity. The scoring also does not distinguish between organic and psychogenic erectile dysfunction, which require different treatment approaches.
Partner-related factors, relationship quality, and situational circumstances can significantly influence responses. The IIEF-5 captures the patient's subjective perception, which may differ from objective erectile function as measured by nocturnal penile tumescence testing or penile Doppler ultrasound.
For related assessments, see IPSS Score and PSA Density.
Disclaimer: This tool is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider with questions about your health.
Calculate the International Prostate Symptom Score (IPSS/AUA-SI) to assess BPH symptom severity. Mild (0–7): watchful waiting. Moderate (8–19): medications. Severe (20–35): surgical evaluation.
UrologyCalculate PSA density (PSAD) to differentiate BPH from prostate cancer. PSAD ≥0.15 ng/mL/mL indicates higher cancer risk and may warrant biopsy even with borderline total PSA levels.